Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $6 to $4.
Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $6 to $4.